Biocarrier and method of using the same

Patent metadata

Field	Value
Publication number	US-9393194-B2
Application number	US-95311010-A
Country	US
Kind code	B2
Filing date	Nov 23, 2010
Priority date	Nov 23, 2010
Publication date	Jul 19, 2016
Grant date	Jul 19, 2016

Abstract

The present invention discloses a biocarrier for delivery of a bioactive substance near/into a target cell, comprising a bioactive substance-loaded core with a first electricity, and one or more block copolymer, each block copolymer comprising a zwitterionic block and an anchoring block with an initial electricity opposite to the first electricity, wherein the anchoring block binds to the core by electrostatic attraction, and the zwitterionic block extends outwardly to increase the biocarrier stability in mammalian blood. Additionally, the present invention also discloses a method of using the biocarrier.

First claim

What is claimed is:

1. A biocarrier for delivery of a bioactive substance near/into a target cell, comprising:
a bioactive substance-loaded core with a positive charge, wherein the bioactive substance-loaded core consists of DNA and a polycation; wherein the polycation is formed by incorporation of a monomer selected from the group consisting of following:

and
one or more block copolymer, each block copolymer comprises a zwitterionic block and an anchoring block, wherein the anchoring block is with a negative charge, the zwitterionic block is formed by incorporation of a zwitterionic monomer, and the zwitterionic monomer is a sulfobetaine compound;
wherein the anchoring block binds to the core by electrostatic attraction, and the zwitterionic block extends outwardly to increase the biocarrier stability in mammalian blood.

2. The biocarrier for delivery of a bioactive substance near/into a target cell as recited in claim 1 , wherein the sulfobetaine compound is selected from the group consisting of the following:

where R1, R2, R3, R4, and R5 are alkyl group; m and n are integers of 2 to 5

and

3. The biocarrier for delivery of a bioactive substance near/into a target cell as recited in claim 1 , wherein the zwitterionic block is a poly(sulfobetaine methacrylate).

4. The biocarrier for delivery of a bioactive substance near/into a target cell as recited in claim 3 , wherein the weight average molecular weight (Mw) of poly(sulfobetaine methacrylate) ranges from 5,000 g/mol to 220,000 g/mol.

5. The biocarrier for delivery of a bioactive substance near/into a target cell as recited in claim 3 , wherein the weight average molecular weight (Mw) of poly(sulfobetaine methacrylate) ranges from 100,000 g/mol to 180,000 g/mol.

6. The biocarrier for delivery of a bioactive substance near/into a target cell as recited in claim 3 , wherein the weight average molecular weight (Mw) of poly(sulfobetaine methacrylate) being 120,000 g/mol provides a plasma clotting time prolonged to 20 minutes at 37° C.

7. The biocarrier for delivery of a bioactive substance near/into a target cell as recited in claim 3 , wherein the weight average molecular weight (Mw) of poly(sulfobetaine methacrylate) ranging from 120,000 g/mol to 180,000 g/mol provides a critical solution temperature at 38° C. to 43° C.

8. The biocarrier for delivery of a bioactive substance near/into a target cell as recited in claim 1 , wherein the anchoring block is polymerized by a monomer selected from the group consisting of following:

9. The biocarrier for delivery of a bioactive substance near/into a target cell as recited in claim 1 , wherein the block copolymer is a diblock copolymer of poly(11-mercaptoundecyl sulfonic acid)-block-poly(sulfobetaine methacrylate).

10. The biocarrier for delivery of a bioactive substance near/into a target cell as recited in claim 9 , wherein the diblock copolymer of poly(11-mercaptoundecyl sulfonic acid)-block-poly(sulfobetaine methacrylate) having the weight average molecular weight (Mw) is more than 18 kDa.

11. The biocarrier for delivery of a bioactive substance near/into a target cell as recited in claim 9 , wherein the diblock copolymer of poly(11-mercaptoundecyl sulfonic acid)-block-poly(sulfobetaine methacrylate) having the average number of repeated units of poly(11-mercaptoundecyl sulfonic acid) is more than 20 and the average number of repeated units of poly(sulfobetaine methacrylate) is more than 40.

Assignees

• Chang Yung
• Shih Yu-Ju
• Univ Chung Yuan Christian

Inventors

• Chang Yung
• Shih Yu-Ju

Classifications

• A61K9/0019 Primary

  Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00) · CPC title

• A61K47/34

  Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers (A61K47/10 takes precedence) · CPC title

• A61K47/48176

  Human Necessities · mapped topic

• A61K47/58

  obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin · CPC title